How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?

HIGHLIGHTS

• who: Xiaoyu Huang from the Unitelma Sapienza University, Italy have published the article: How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?, in the Journal: (JOURNAL)
• what: In this study, a total of 139 EOC patients receiving bevacizumab treatment were analyzed. The primary outcome of the study was PFS, calculated from the date of randomization to the date of the first observed indication of cancer progression or death. Although the study has certain limitations, such as its retrospective nature and lack of external validation for . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.